Results 211 to 220 of about 237,523 (354)

Eosinophil extracellular trap cell death-derived DNA traps: Their presence in secretions and functional attributes.

Journal of Allergy and Clinical Immunology, 2016
S. Ueki, Y. Konno, M. Takeda, Y. Moritoki, M. Hirokawa, Y. Matsuwaki, K. Honda, N. Ohta, Shiori Yamamoto, Yuri Takagi, Atsushi Wada, P. Weller   +11 more
semanticscholar   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

CT image-based machine learning models for predicting blood eosinophil levels in acute exacerbation of chronic obstructive pulmonary disease. [PDF]

BMC Pulm Med
Zhao S, Wu Y, Du L, Jia H, Monkam P, Qian W, Wang R, Xia S, Qi S.   +8 more
europepmc   +1 more source

The reproducibility of COPD blood eosinophil counts

European Respiratory Journal, 2018
T. Southworth, Gussie Beech, P. Foden, U. Kolsum, Dave Singh   +4 more
semanticscholar   +1 more source

Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases—An update

British Journal of Clinical Pharmacology, EarlyView.
Aim Clinically, interstitial lung disease (ILD) is a heterogeneous group of respiratory disorders. Due to their low incidence, pharmacovigilance database analysis is useful to detect them. Precise diagnosis is challenging as well as coding in these databases. Query criteria are among the key elements for a good signal detection.
Romane Freppel, Adeline Benis, Philippe Bonniaud, Jean‐Luc Faillie, Aurélie Grandvuillemin   +4 more
wiley   +1 more source

Comment on: Eosinophilic granulomatosis with polyangiitis across the eosinophilic spectrum: from molecular mechanisms to practical differential diagnosis and targeted therapy. [PDF]

Reumatologia
Kosałka-Węgiel J, Korkosz M.
europepmc   +1 more source

Eosinophils and eosinophil-associated diseases: An update.

Journal of Allergy and Clinical Immunology, 2017
Jeremy A O'Sullivan, B. Bochner
semanticscholar   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, EarlyView.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

Rapidly progressive squamous lung cancer with peripheral blood eosinophilia in a 25-year-old woman: A case report. [PDF]

Oncol Lett
Zhang M, Fan H, Sun C, Li D, Gan J, He Y, Chen J.   +6 more
europepmc   +1 more source

IL-33 Elicits LTC₄ Synthesis in Allergic Inflammation via ST2-Mediated Activation of Eosinophils. [PDF]

Eur J Immunol
Rosário-Garcia VF, Guimaraes-Ferreira E, Brito-Leite Y, Oliveira JF, Santos-da-Silva J, Amorim NRT, Muniz VS, Bolini L, Werneck MBF, Canetti C, Diaz BL, Bandeira-Melo C.   +11 more
europepmc   +1 more source